In this issue:
Maridebart cafraglutide reduces bodyweight in obesity
Efsitora for type 2 diabetes: QWINT-1, 3 and 4
Cagrilintide-semaglutide for overweight/obesity and type 2 diabetes
Orforglipron in early type 2 diabetes
Retatrutide reduces fat mass in type 2 diabetes
CV events with sulfonylureas vs. DPP-4 inhibitors
Ophthalmic complications with GLP-1 agonists
Please login below to download this issue (PDF)